Overview of Dr. Kayaleh
Dr. Omar Kayaleh is an oncologist in Orlando, FL and is affiliated with Orlando Health Orlando Regional Medical Center. He received his medical degree from University of Florida College of Medicine and has been in practice 32 years. Dr. Kayaleh accepts several types of health insurance, listed below. He is one of 74 doctors at Orlando Health Orlando Regional Medical Center who specialize in Oncology. He has 7 publications and over 250 citings.
Office
1400 South Orange Ave.
Orlando, FL 32806
Education & Training
- Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 1993 - 1996
- MedStar Franklin Square Medical CenterResidency, Internal Medicine, 1985 - 1988
- University of Florida College of MedicineClass of 1985
Certifications & Licensure
- FL State Medical License 1988 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Start of enrollment: 2008 Jun 01
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
- Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Start of enrollment: 2011 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 33 citationsExpression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and TherapyUmesh T. Sankpal, Pius Maliakal, Debashish Bose, Omar Kayaleh, Daniel Buchholz
Current Medicinal Chemistry. 2012-07-31 - 183 citationsSafety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, hea...Bohuslav Melichar, Antoine Adenis, A. Craig Lockhart, Jaafar Bennouna, E. Claire Dees
The Lancet. Oncology. 2015-04-01 - 1 citationsA phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.Ruchi Singhal, Sherise C Rogers, Ji-Hyun Lee, Brian Ramnaraign, Ilyas Sahin
Future Oncology. 2023-09-01
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Aetna Whole Health Banner Health Network
AvMed Health Open Access
BCBS Arizona BlueAlliance Network
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOCoventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Health Net Arizona HMO
Health Net Arizona HMO ExcelCare Network
Health Net Arizona PPO/POS
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: